Lapatinib(CAS: 231277-92-2)

Lapatinib is a small molecule kinase inhibitor with the chemical formula C22H26N2O2S. It is known for its ability to inhibit the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), making it a valuable compound in cancer research and treatment. Its molecular weight is approximately 382.5 g/mol and it is typically a white to off-white solid at room temperature.

Lapatinib is primarily used in the treatment of certain types of breast cancer, particularly those that are resistant to other HER2-targeted therapies. It is also utilized in pharmaceutical research for its anti-cancer properties and as a tool for studying EGFR and HER2 signaling pathways. In industrial applications, it may be used as a chemical intermediate or in drug development processes.

Lapatinib is generally considered safe when used under medical supervision for its intended therapeutic purposes. However, it may cause side effects such as diarrhea, fatigue, and skin reactions. Proper safety protocols, including handling in well-ventilated areas and following regulatory guidelines, should be observed to minimize risks during storage, transportation, and use.

Lapatinib should be stored in a cool, dry, and dark place, preferably at a temperature between 15°C and 30°C. It is important to maintain low humidity and protect it from light exposure to ensure stability. The compound should be kept in a sealed container and stored away from incompatible materials to prevent degradation or contamination.